Single-cycle adenovirus vectors in the current vaccine landscape

References

• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Reviews Immunol. 2012;12(8):592–605. Epub 2012/ 07/26. DOI:10.1038/nri3251
   PubMed Web of Science ®Google Scholar
• Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol. 2013;87(9):4907–4922. Epub 2013/ 02/15. DOI:10.1128/JVI.02954-12
   PubMed Web of Science ®Google Scholar
• Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356:152–154.
   PubMed Web of Science ®Google Scholar
• Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993;90:11478–11482.
   PubMed Web of Science ®Google Scholar
• Davis HL, Michel M-L. Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet. 1993;2:1847–1851.
   PubMed Web of Science ®Google Scholar
• Conry RM, LoBuglio AF, Kantor J, et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res. 1994;54:1164–1168.
   PubMed Web of Science ®Google Scholar
• Han R, Cladel NM, Reed CA, et al. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol. 1999;73(8): 7039–7043. PubMed PMID: 10400806.
   PubMed Web of Science ®Google Scholar
• Ertl HC, Xiang ZQ. Genetic immunization. Viral Immunol. 1996;9(1):1–9.
   PubMed Web of Science ®Google Scholar
• Chattergoon M, Boyer J, Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB Journal. 1997;11(10):753–763.
   PubMed Web of Science ®Google Scholar
• Barry MA. Genetic immunization: applying recombinant DNA technology in the immune system to develop new vaccines. Curr Opin Drug Discov Dev. 1999;2(2):118–128.
   PubMedGoogle Scholar
• Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther. 2009;17(8): 1333–1339. PubMed PMID: 19513019.
   PubMed Web of Science ®Google Scholar
• Barry MA. Recombinant vector vaccines for the prevention and treatment of HIV infection. Drugs Future. 2011;36(11):833–845.
   Web of Science ®Google Scholar
• Shashkova EV, May SM, Barry MA. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology. 2009;394:311–320. Epub Sep 17. PubMed PMID: 19765790.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Barry MA. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology. 2014;462–463:158–165. Epub 2014/07/06. PubMed PMID: 24996029; PMCID: PMC4125442. DOI:10.1016/j.virol.2014.05.030
   PubMed Web of Science ®Google Scholar
• Peng B, Wang LR, Gomez-Roman VR, et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol. 2005;79(16):10200–10209. PubMed PMID: 16051813.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Nehete P, Sastry KJ, et al. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol. 2015;89(1):669–675. Epub 2014/ 10/31. PubMed PMID: 25355873; PMCID: PMC4301142. DOI:10.1128/jvi.02184-14
   PubMed Web of Science ®Google Scholar
• Crosby CM, Matchett WE, Anguiano-Zarate SS, et al. Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses. J Virol. 2017;91(2). PubMed PMID: 27807231; PMCID: PMC5215357. DOI:10.1128/JVI.00720-16
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector ebola vaccine–preliminary report. N Engl J Med. 2015;373(8):776. PubMed PMID: 26287857. DOI:10.1056/NEJMc1505499
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518. PubMed PMID: 28017403; PMCID: PMC5364328. DOI:10.1016/S0140-6736(16)32621-6
   PubMed Web of Science ®Google Scholar
• Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008;14(31): 4849–4860. PubMed PMID: 18756591; PMCID: PMC2739936.
   PubMed Web of Science ®Google Scholar
• Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: updates on clinical management. World J Gastroenterol. 2014;20(31):10658–10667. PubMed PMID: 25152570; PMCID: PMC4138447. DOI:10.3748/wjg.v20.i31.10658
   PubMed Web of Science ®Google Scholar
• Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012;12(9):2457–2464. PubMed PMID: 22594993; PMCID: PMC3510308. DOI:10.1111/j.1600-6143.2012.04087.x
   PubMed Web of Science ®Google Scholar
• Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50(11):1439–1447. PubMed PMID: 20426575. DOI:10.1086/652438
   PubMed Web of Science ®Google Scholar
• Bialas KM, Swamy GK, Permar SR. Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. Clin Perinatol. 2015;42(1):61–75, viii. PubMed PMID: 25677997; PMCID: PMC4328139. DOI:10.1016/j.clp.2014.10.006
   PubMed Web of Science ®Google Scholar
• Bialas KM, Permar SR. The march towards a vaccine for congenital CMV: rationale and models. PLoS Pathogens. 2016;12(2):e1005355. PubMed PMID: 26866914; PMCID: PMC4750955. DOI:10.1371/journal.ppat.1005355
   PubMed Web of Science ®Google Scholar
• Lanzieri TM, Chung W, Flores M, et al. Congenital cytomegalovirus longitudinal study G. Hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatrics. 2017;139(3):e20162610. PubMed PMID: 28209771; PMCID: PMC5330400. DOI:10.1542/peds.2016-2610
   PubMed Web of Science ®Google Scholar
• Lanzieri TM, Leung J, Caviness AC, et al. Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol. 2017;37(7):875–880. PubMed PMID: 28383538; PMCID: PMC5562509. DOI:10.1038/jp.2017.41
   PubMed Web of Science ®Google Scholar
• Lopez AS, Lanzieri TM, Claussen AH, et al. Congenital cytomegalovirus longitudinal study G. Intelligence and academic achievement with asymptomatic congenital cytomegalovirus infection. Pediatrics. 2017;140(5). PubMed PMID: 29066580; PMCID: PMC5654402. DOI:10.1542/peds.2017-1517
   Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–363. PubMed PMID: 17542052. DOI:10.1002/rmv.544
   PubMed Web of Science ®Google Scholar
• Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41(2):57–62. PubMed PMID: 17959414. DOI:10.1016/j.jcv.2007.09.004
   PubMed Web of Science ®Google Scholar
• Bartlett AW, McMullan B, Rawlinson WD, et al. Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: a systematic review. Rev Med Virol. 2017;27:e1938. PubMed PMID: 28876493. DOI:10.1002/rmv.1938
   Web of Science ®Google Scholar
• Swanson EC, Schleiss MR. Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr Clin North Am. 2013;60:335–349.
   PubMed Web of Science ®Google Scholar
• Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43(3):331–339. PubMed PMID: 16804849. DOI:10.1086/505498
   PubMed Web of Science ®Google Scholar
• Harvala H, Stewart C, Muller K, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893–898. PubMed PMID: 23508914. DOI:10.1002/jmv.23539
   PubMed Web of Science ®Google Scholar
• Choudhry A, Mathena J, Albano JD, et al. Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016;34(38):4558–4564. PubMed PMID: 27475474. DOI:10.1016/j.vaccine.2016.07.033
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006;12(5):216–222. Epub 2006/ 04/20. DOI:10.1016/j.molmed.2006.03.007
   PubMed Web of Science ®Google Scholar
• Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55: 355–372. PubMed PMID: 14746526.
   PubMed Web of Science ®Google Scholar
• Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010;5(5):386–390. PubMed PMID: 20978378; PMCID: PMC2967414. DOI:10.1097/COH.0b013e32833cfe4c
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415(6869): 331–335. PubMed PMID: 11797011.
   PubMed Web of Science ®Google Scholar
• Cohen J. Infectious disease. Ebola vaccines racing forward at record pace. Science. 2014;345(6202):1228–1229. Epub 2014/ 09/13. DOI:10.1126/science.345.6202.1228
   PubMed Web of Science ®Google Scholar
• Zhang Q, Seto D. Chimpanzee adenovirus vector ebola vaccine–preliminary report. N Engl J Med. 2015;373(8):775–776. PubMed PMID: 26287858. DOI:10.1056/NEJMc1505499#SA1
   PubMed Web of Science ®Google Scholar
• Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nature Reviews. 2014;12(11):765–771. PubMed PMID: 25296195; PMCID: PMC4237164. DOI:10.1038/nrmicro3360
   Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473(7348):523–527. PubMed PMID: 21562493; PMCID: PMC3102768. DOI:10.1038/nature10003
   PubMed Web of Science ®Google Scholar
• Malkevitch N, Patterson LJ, Aldrich K, et al. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol. 2003;170(8): 4281–4289. PubMed PMID: 12682263.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lou Y, Pinczewski J, et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine. 2003;21(25–26): 4022–4035. PubMed PMID: 12922139.
   PubMed Web of Science ®Google Scholar
• Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol. 2004;78(5): 2212–2221. PubMed PMID: 14963117.
   PubMed Web of Science ®Google Scholar
• Zhao J, Voltan R, Peng B, et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology. 2005;342(1): 1–12. PubMed PMID: 16109434.
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006;308(1–2): 53–67. PubMed PMID: 16343526.
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Florese RH, Peng B, et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr. 2006;43(3): 270–277. PubMed PMID: 16940858.
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Grimes GJ Jr., Potti GK, et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine. 2006;24(23): 5064–5072. PubMed PMID: 16621178.
   PubMed Web of Science ®Google Scholar
• Peng B, Voltan R, Cristillo AD, et al. Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS. 2006;20(17): 2149–2157. PubMed PMID: 17086054.
   PubMed Web of Science ®Google Scholar
• Demberg T, Florese RH, Heath MJ, et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2007;81(7): 3414–3427. PubMed PMID: 17229693.
   PubMed Web of Science ®Google Scholar
• Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009;83(2):791–801. PubMed PMID: 18971271; PMCID: PMC2612365. DOI:10.1128/JVI.01672-08
   PubMed Web of Science ®Google Scholar
• Morgan C, Marthas M, Miller C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Medicine. 2008;5(8): e173. PubMed PMID: 18700814.
   PubMed Web of Science ®Google Scholar
• Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol. 2009;28(1): 20–48. PubMed PMID: 19241252.
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PloS One. 2009;4(3): e5059. PubMed PMID: 19333387.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Barry MA. Transgene expression and host cell responses to replication-defective, single-cycle, and replication-competent adenovirus vectors. Genes (Basel). 2017;8(2). PubMed PMID: 28218713; PMCID: PMC5333068. DOI:10.3390/genes8020079
   PubMed Web of Science ®Google Scholar
• Widman DG, Frolov I, Mason PW. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv Virus Res. 2008;72:77–126. PubMed PMID: 19081489. DOI:10.1016/S0065-3527(08)00402-8
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9(13):1909–1917. PubMed PMID: 9741429. DOI:10.1089/hum.1998.9.13-1909
   PubMed Web of Science ®Google Scholar
• Schiedner G, Hertel S, Kochanek S. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther. 2000;11(15):2105–2116. PubMed PMID: 11044912. DOI:10.1089/104303400750001417
   PubMed Web of Science ®Google Scholar
• McChesney MB, Miller CJ. New directions for HIV vaccine development from animal models. Curr Opin HIV AIDS. 2013;8(5):376–381. 10.1097/COH.0b013e328363d3a2. PubMed PMID: 23836045.
   PubMed Web of Science ®Google Scholar
• STEP study: disappointing, but not a failure. Lancet. 2007;370(9600):1665. PubMed PMID: 18022020.
   PubMed Web of Science ®Google Scholar
• Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205(1): 7–12. PubMed PMID: 18195078.
   PubMed Web of Science ®Google Scholar
• Steinbrook R. One step forward, two steps back–will there ever be an AIDS vaccine? N Engl J Med. 2007;357(26): 2653–2655. PubMed PMID: 18160684.
   PubMed Web of Science ®Google Scholar
• Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010;5(5): 357–361. PubMed PMID: 20978374.
   PubMed Web of Science ®Google Scholar
• Byrareddy SN, Ayash-Rashkovsky M, Kramer VG, et al. Live attenuated Rev-independent Nef SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PloS One. 2013;8(9):e75556. PubMed PMID: 24098702; PMCID: PMC3787041. DOI:10.1371/journal.pone.0075556
   PubMed Web of Science ®Google Scholar
• Staprans SI, Feinberg MB. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines. 2004 Epub 2004/ 08/03;3(4 Suppl):S5–32. PubMed PMID: 15285703.
   PubMedGoogle Scholar
• Tenbusch M, Ignatius R, Nchinda G, et al. Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PloS One. 2012;7(6):e39038. Epub 2012/ 06/22. DOI:10.1371/journal.pone.0039038
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89–93. PubMed PMID: 22217938; PMCID: 3271177. DOI:10.1038/nature10766
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, et al. Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys. Science. 2015. PubMed PMID: 26138104. DOI:10.1126/science.aab3886
   Web of Science ®Google Scholar
• Morral N, O’Neal W, Zhou H, et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther. 1997;8(10):1275–1286.
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9): 4654–4663. PubMed PMID: 17329340.
   PubMed Web of Science ®Google Scholar
• Dhar D, Spencer JF, Toth K, et al. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol. 2009;83(5):2130–2139. PubMed PMID: 19073718; PMCID: PMC2643738. DOI:10.1128/JVI.02127-08
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Nehete BP, et al. Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines. Viruses. 2009;1(3):920. Epub 2010/ 01/29. DOI:10.3390/v1030920
   PubMed Web of Science ®Google Scholar
• Weaver EA, Nehete PN, Nehete BP, et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PloS One. 2013;8(7):e67574. Epub 2013/ 07/12. DOI:10.1371/journal.pone.0067574
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Gao GP, Reyes-Sandoval A, et al. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003;77(20): 10780–10789. PubMed PMID: 14512528.
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4(115):115ra2. PubMed PMID: 22218691; PMCID: PMC3627206. DOI:10.1126/scitranslmed.3002925
   PubMed Web of Science ®Google Scholar
• Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998;27(5): 1194–1200. PubMed PMID: 9827268.
   PubMed Web of Science ®Google Scholar
• Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol. 2006;44(10): 3781–3783. PubMed PMID: 17021110.
   PubMed Web of Science ®Google Scholar
• Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263–8271.
   PubMed Web of Science ®Google Scholar
• Pinto AR, Fitzgerald JC, Giles-Davis W, et al. Induction of CD8(+) T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol. 2003;171(12):6774–6779.
   PubMed Web of Science ®Google Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81(12): 6594–6604. PubMed PMID: 17428852.
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Korioth-Schmitz B, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine. 2009;27(42): 5837–5845. PubMed PMID: 19660588.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Blejer A, Lasaro MO, et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther. 2007;15(3): 608–617. PubMed PMID: 17228314.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172(10): 6290–6297. PubMed PMID: 15128818.
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Sumida SM, Holterman L, et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 2005;79(15): 9694–9701. PubMed PMID: 16014931.
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med. 1997;3(6):651–658.
   PubMed Web of Science ®Google Scholar
• Takada A, Feldmann H, Stroeher U, et al. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol. 2003;77(2): 1069–1074. PubMed PMID: 12502822; PMCID: PMC140786.
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10): 5458–5465. PubMed PMID: 15113924; PMCID: PMC400370.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82(11):5664–5668. PubMed PMID: 18385248; PMCID: PMC2395203. DOI:10.1128/JVI.00456-08
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26(52):6894–6900. PubMed PMID: 18930776; PMCID: PMC3398796. DOI:10.1016/j.vaccine.2008.09.082
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathogens. 2008;4(11):e1000225. PubMed PMID: 19043556; PMCID: PMC2582959. DOI:10.1371/journal.ppat.1000225
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–7304. PubMed PMID: 19386702; PMCID: PMC2704787. DOI:10.1128/JVI.00561-09
   PubMed Web of Science ®Google Scholar
• O’Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10(8):1349–1358.
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, et al. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001;75(10): 4792–4801. PubMed PMID: 11312351.
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 2002;13(15): 1887–1900. PubMed PMID: 12396620.
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77(11): 6305–6313. PubMed PMID: 12743287.
   PubMed Web of Science ®Google Scholar
• Jaworski JP, Krebs SJ, Trovato M, et al. Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PloS One. 2012;7(2):e31464. PubMed PMID: 22359593; PMCID: PMC3281069. DOI:10.1371/journal.pone.0031464
   PubMed Web of Science ®Google Scholar
• Pissani F, Malherbe DC, Schuman JT, et al. Improvement of antibody responses by HIV envelope DNA and protein co-immunization. Vaccine. 2014;32(4):507–513. PubMed PMID: 24280279; PMCID: PMC3926420. DOI:10.1016/j.vaccine.2013.11.022
   PubMed Web of Science ®Google Scholar
• Sridhar S. Clinical development of Ebola vaccines. Ther Adv Vaccines. 2015;3(5–6):125–138. PubMed PMID: 26668751; PMCID: PMC4667768. DOI:10.1177/2051013615611017
   PubMedGoogle Scholar
• Couch RB, Chanock RM, Cate TR, et al. Immunization with types 4 and 7 adenovirus by selective infection of the intestinal tract. Am Rev Respir Dis. 1963;88(SUPPL):394–403.
   Google Scholar
• Turner MA, Middha S, Hofherr SE, et al. Comparison of the life cycles of genetically distant species C and species D human adenoviruses Ad6 and Ad26 in human cells. J Virol. 2015;89(24):12401–12417. PubMed PMID: 26423951; PMCID: PMC4665244. DOI:10.1128/JVI.01534-15
   PubMed Web of Science ®Google Scholar